Wendy Shao
Company Building Partner
Wendy Shao joins Material Impact as a Partner.
Her areas of interest include life science tools and technologies, advanced manufacturing, services and processing for biopharma industry, synthetic biology, biomaterials innovation, measurement equipment, medical devices and diagnostics, and digital health transformation.
She is dedicated to driving transformative outcomes for our portfolio companies in global market reach through strategic partnership and innovative deal-making.
Through her career at Bio-Techne, Abbott, Guidant and HP, Wendy successfully completed over 100 transactions, totaling $30B+ in drug delivery technologies for site specific therapies, drug eluting stents, valve replacement therapies, minimally invasive surgeries, remote patient management platforms, cell gene therapies, imaging technologies, specialty chemicals, proteins and antibodies, proteomics, IVD and specialty media for bioproduction. She worked on the transformative deal of the acquisition of Guidant by Boston Scientific involving a combination of cash and stock worth $27 billion & Abbott Labs buying the vascular intervention business of Guidant for ~$4.5 billion. Her expertise spans M&A, licensing, JVs, spin-outs, venture investing, co-development & strategic alliances. Wendy has a passion for identifying high-potential opportunities, overseeing due diligence, negotiating complex deals, managing post deal integration and crafting strategies that generate substantial value and investment return. Wendy also served as board director and board observer role in the investments.
Wendy held leadership positions with multinational companies, where she assumed full P&L responsibility. With more than a decade of executive management experience, Wendy built companies from the ground up and created significant return for shareholders. She served as managing director & Chairman of the board, navigating complex regulatory & commercial environment, overseeing operations from research and development, finance, HR, manufacturing, regulatory compliance and commercialization particularly in Asia and Greater China. She was regarded for her abilities to develop and execute commercial strategies that meet revenue goals set by the board, identify target markets, manage competitive positioning and drive growth, profitability & operational success.
Wendy supported NIH entrepreneurial initiatives, and was a review committee member of The NCI SBIR Investor Initiative.
Wendy loves hiking and traveling. She is very active in various venture communities in Silicon Valley and loves to mentor and coach start-ups.
Sign up for news and views that make an impact.